Live Chat

CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 74 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder.Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Handel Vir Biotechnology VIR

Sælge
 Køb

VirBiotechnology live diagram

5m 15m 30m 1h 4h 1d 1w

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

Seneste nyheder

Frances Wang 2024 Dec 23, 16:00

SPOT stock price: Spotify stock reaches all-time highs

Stocks
Frances Wang 2024 Dec 23, 16:00

DRCT stock price today: Direct Digital Holdings spikes on high-volume move

Stocks
Frances Wang 2024 Dec 23, 16:00

Stock Market Today: Dow Jones Closes Higher for Third Consecutive Day

Stocks
GDP data
Dyogenes Diniz 2024 Dec 22, 17:00

Morning Note: GDP in the UK, Spain and Canada to Shake Markets Today

Frances Wang 2024 Dec 22, 16:00

Bitcoin ETFs Experience Record Outflows Amid Crypto Market Decline

Cryptocurrencies ETFs
Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies

Info

Spread

0.06

Spread (%)

0.8108 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market lukket

Torsdag

14:31 - 20:59

Mandag

14:31-20:59

Tirsdag

14:31-17:59

Fredag

14:31-20:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

1010864832

Aktier udestående

137720000

Indtjeningsdato (Næste)

0000-00-00

Udbytteprocent

Ex-udbyttedato

Forventet årlig udbyttesats

0

Forventet årlig udbytteprocent

0

EPS

-3.93

Få mere at vide om dette instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre

Handl nu

Handl nu

Handl nu

Handl nu
Relaterede instrumenter
Trustpilot
Live Chat